An observational study in Coronary Artery Disease, sponsored by Baker Heart and Diabetes Institute. Recruiting at 2 sites in Australia. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Baker Heart and Diabetes Institute · Observational
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.
Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago
A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion Criteria:
In cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic Test: Coronary CT
In matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
Diagnostic Test: Coronary CT
Screening/Management Plan
Proportion of evaluated patients who should undergo CAD prevention
High clinical risk, or intermediate risk with CAC score \>0
Time frame: 3 years
Proportion with critical CAD
Coronary stenosis \>70% by CT coronary angiogram
Time frame: 3 years
Proportion at intermediate clinical risk
Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)
Time frame: 3 years
Statin responsiveness
Change in plaque volume
Time frame: 3 year follow-up
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baker Heart and Diabetes Institute